Skip to main content

KYGEVVI

Generic: doxecitine and doxribtimine

Verified·Oct 26, 2026
Manufacturer
Adaptimmune
NDC
50474-350
RxCUI
2737535
Route
ORAL
ICD-10 indication
L28.1

Affordability Check

How much will you actually pay for KYGEVVI?

In 30 seconds, see every legitimate way to afford KYGEVVI — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About KYGEVVI

What is this medication? Tecelra is a specialized prescription medication used to treat adults with a rare type of cancer called synovial sarcoma. This treatment is intended for patients whose cancer is metastatic or cannot be removed by surgery and who have already received prior chemotherapy. It is specifically designed for individuals whose tumors express the MAGE-A4 protein and who have specific human leukocyte antigen types, as determined by a healthcare provider through specialized testing. This medication is a type of gene-modified autologous T-cell immunotherapy. The treatment process involves collecting a patient's own T-cells, which are then genetically engineered in a laboratory to recognize and target the MAGE-A4 protein on cancer cells. After the modified cells are prepared, they are infused back into the patient to help the immune system fight the cancer. Due to the complexity of the procedure and potential side effects, it is administered in certified healthcare settings under close medical supervision.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Not Publicly Available
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How KYGEVVI appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

3%

180 of 5,499 plans

Most common tier

Tier 5

On 95% of covering formularies

Prior authorization required

100%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)1
5%
Tier 5 (specialty)18
95%

Step therapy: 0% of formularies

Quantity limits: 16% of formularies

Coverage breadth: 19 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.